Colonoscopy

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

FUJIFILM Europe launches new virtual scale solution to address challenges faced by endoscopists in polyp measurement

Retrieved on: 
Friday, April 21, 2023
ESGE, EYE, Fujifilm, CAD, Cancer, Innovation system, Research, Large intestine, Associate, Colon, Colorectal cancer, SCALE, Patient, Physician, Hearing, Colonoscopy, Diagnosis, Polyp, Medical imaging, Gastroenterology, Humanitas University

To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.

Key Points: 
  • To support endoscopists, FUJIFILM Europe has launched SCALE EYE, a virtual scale solution designed to support endoscopists in estimating the size of lesions in the colon.
  • Integrated into FUJIFILM's ELUXEO Ultra platform, SCALE EYE enables endoscopists to measure polyps more accurately and as a result, support physicians to determine the treatment needed by simply pressing a switch.
  • Despite 90 percent of the endoscopists agreeing on the importance of polyp measurement, the majority use visual estimation, open biopsy forceps, or endoscopic rulers, rather than innovative solutions.
  • [2]
    Prof Cesare Hassan, Associate Professor of Gastroenterology, Humanitas University, Italy said: "SCALE EYE is a disruptive technology by Fujifilm.

BESCREENED BLOOD-BASED COLORECTAL CANCER TEST AVAILABLE AT ANY LAB TEST NOW LOCATIONS ACROSS THE COUNTRY

Retrieved on: 
Thursday, April 20, 2023
Partnership, LDT, CRC, Survival, Cancer, Woman, Colorectal cancer, Risk, Colonoscopy, McGrath, Neoplasm, Ageing, Research, Disease, Medical imaging, PHOENIX

PHOENIX, April 20, 2023 /PRNewswire/ -- Beacon Biomedical announced the availability of its BeScreened Colorectal Cancer (CRC) test at Any Lab Test Now locations across the nation. The test requires a single-tube blood-draw and measures three CRC related tumor associated proteins. With 94 percent accuracy, BeScreened detects CRC across all stages, combining results relationally into a simple and accurate "positive" or "negative" likelihood of CRC or precancerous polyps' presence or absence.

Key Points: 
  • PHOENIX, April 20, 2023 /PRNewswire/ -- Beacon Biomedical announced the availability of its BeScreened Colorectal Cancer (CRC) test at Any Lab Test Now locations across the nation.
  • Its availability across the country at Any Lab Test Now locations gives the consumer access like never before.
  • "Any Lab Test Now is passionate about this innovative new screening for colon cancer," explains Clarissa Bradstock, CEO of Any Lab Test Now, a direct access lab testing franchise with more than 215 locations nationwide.
  • Tests are available now, across the country at Any Lab Test Now location as well as online.

InterVenn Biosciences to Present Clinical Data on Circulating Serum Glycoproteins for Unprecedented Pre-Cancer Detection as “Poster of Distinction” at Digestive Disease Week 2023

Retrieved on: 
Wednesday, April 19, 2023
Oncology, Health, Medical Devices, Other Health, General Health, Pharmaceutical, Biotechnology, Abstract, DNA, Circulating tumor DNA, Glycoprotein, CRC, Serum, Carolyn Bertozzi, American Gastroenterological Association, Adenoma, DDW, AGA, MD, Patient, Cancer, Colorectal cancer, Colonoscopy, Mortality, Neoplasm, Conference, AA, Disease, Pharmaceutical industry, Medical imaging

InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).

Key Points: 
  • InterVenn Biosciences , the life science company pioneering glycoproteomics, today announced new clinical data that demonstrates the power of InterVenn’s proprietary biomarker discovery platform, GlycoVision™ , to detect advanced adenomas (AA) and colorectal cancer (CRC).
  • The data will be presented as a “Poster of Distinction" at the 2023 Digestive Disease Week Conference (DDW), being held May 6-9, in Chicago, IL.
  • GlycoVision’s method of assessing circulating serum glycoproteins is unlike any non-invasive test for CRC that’s on the market, which primarily rely on circulating tumor DNA (ctDNA).
  • Details on the time and location of the presentation are as follows:
    Warning Signs from the Crypt: Circulating Aberrant Glycosylation Signatures Correlate with Advanced Adenoma and Colorectal Cancer

Ferring to Present Analyses of Data for REBYOTA™ (fecal microbiota, live – jslm), the First FDA-Approved Microbiome-Based Treatment for the Prevention of Recurrent C. difficile Infection, at DDW 2023

Retrieved on: 
Tuesday, April 18, 2023
Health, FDA, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Infection, Clostridioides difficile infection, Ferring Pharmaceuticals, Gastrointestinal disease, Beth Israel Deaconess Medical Center, Safety, Multimedia, Harvard Medical School, Yale School of Medicine, Inflammatory bowel disease, DDW, Clostridioides difficile, Patient, Colonoscopy, Poster, Immunodeficiency, Congress, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Pharmaceutical industry

Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™ (fecal microbiota, live – jslm) at Digestive Disease Week® ( DDW 2023 ).

Key Points: 
  • Ferring Pharmaceuticals today announced it will present analyses of data for REBYOTA™ (fecal microbiota, live – jslm) at Digestive Disease Week® ( DDW 2023 ).
  • REBYOTA is not indicated for the treatment of C. diff infection.
  • Oral Presentation: 700 – Description – Safety and efficacy of RBX2660 in reducing recurrent Clostridioides difficile infection in immunocompromised patients.
  • Gastroenterology, Hamden, Conn.; Assistant Clinical Professor of Medicine, Yale University School of Medicine, New Haven, Conn.

BGI Global Colorectal Cancer Survey Reveals Awareness Gaps and Affordability Concerns

Retrieved on: 
Friday, April 7, 2023
Learning, CRC, Civil service commission, World Health Day, BGI Group, Genomics, Survival, Health For All, Health, Cancer, National Comprehensive Cancer Network, Universal quantification, Doctor of Philosophy, NCCN, Colonoscopy, Patient, Risk, Colorectal cancer, Diagnosis, Family, News, European Commission, Dairy, Health insurance

HONG KONG, April 7, 2023 /PRNewswire/ -- To uncover attitudes and the biggest challenges facing colorectal cancer (CRC) awareness and screening, BGI Genomics today released its State of Colorectal Cancer Awareness Report, marking the first-ever global survey report on the world's third most common cancer.

Key Points: 
  • HONG KONG, April 7, 2023 /PRNewswire/ -- To uncover attitudes and the biggest challenges facing colorectal cancer (CRC) awareness and screening, BGI Genomics today released its State of Colorectal Cancer Awareness Report, marking the first-ever global survey report on the world's third most common cancer.
  • This inaugural report seeks to better understand the global state of CRC awareness, as well as attitudes and actions towards CRC screening for average risk groups and CRC screening for hereditary genetic risk groups.
  • Despite 51.5% reporting that there is insufficient information about CRC and 34.5% citing costs holding them back from CRC screening, the report reveals several optimistic findings.
  • To read and view country or region-level comparisons, please see link to access the full BGI Genomics State of Colorectal Cancer Awareness Report 2023.

BESCREENED BLOOD-BASED COLORECTAL CANCER TEST PROVIDES AFFORDABLE EARLY DETECTION AND WITHOUT THE MESS

Retrieved on: 
Wednesday, March 15, 2023
Cancer, Biomedicine, Survival, Risk, Probability, Colorectal cancer, Death, LDT, CRC, Woman, Lung compliance, Research, Disease, Colonoscopy, McGrath, Statistics, Family, Video, Ageing, Collection, Pharmaceutical industry, Medical imaging, PHOENIX

PHOENIX, March 15, 2023 /PRNewswire/ -- Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer (CRC) test. BeScreened improves access and affordability to CRC screening as a blood-draw instead of a fecal collection. The company is mission-based, led by Jason McGrath, a colon cancer survivor. BeScreened is determined to improve early detection of CRC which significantly improves survival rates and dramatically reduces the cost of treatment.

Key Points: 
  • PHOENIX, March 15, 2023 /PRNewswire/ -- Beacon Biomedical announced the commercial release of the BeScreened Colorectal Cancer (CRC) test.
  • BeScreened is determined to improve early detection of CRC which significantly improves survival rates and dramatically reduces the cost of treatment.
  • Colorectal Cancer is the second deadliest and second most costly cancer in the United States.
  • "As a simple, easy to adopt, and highly accurate blood-based test for CRC screening, BeScreened was developed to address this very problem."

Health Catalyst, GIQuIC Team Up to Power the Nation's Only Gastroenterology-Focused Clinical Registry

Retrieved on: 
Tuesday, March 14, 2023
ERCP, American College of Gastroenterology, EUS, Colonoscopy, Patient, ASGE, MMM, American College, American Society for Gastrointestinal Endoscopy, ACG, FACG, Data management, EBT, Gastrointestinal Endoscopy, Data collection, Society, EGD, Inflammatory bowel disease, HCAT, SALT, IBD, Partnership, Nursing, Medical device, MD

As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.

Key Points: 
  • As noted in Health Catalyst's Q4 2022 earnings call announcement, GIQuiC which offers the only national gastroenterology-focused clinical registry, will utilize ARMUS by Health Catalyst's HYBRID Clinical Registry and Reporting solution to advance the extraction process, including a streamlined user experience, enhanced data capture process, and improved reporting.
  • "This collaboration will enhance the service we already provide to our registry participants by allowing GIQuIC to leverage the depth and breadth of offerings and prior experience and success Health Catalyst has with respect to registry services and healthcare analytics.
  • "Data abstraction and registry reporting are critical functions of healthcare organizations, and we are delighted GIQuIC has selected Health Catalyst to power this important work," said Dan Burton, CEO of Health Catalyst.
  • "We look forward to an enduring partnership with the GIQuIC team and registry participants."

AMSURG Advocates for Timely Colorectal Cancer Screening and Education

Retrieved on: 
Friday, March 10, 2023
Surgery, Women, Hospitals, Men, Radiology, Managed Care, Health, Consumer, Oncology, Cancer Moonshot, Cancer, Colonoscopy, Colorectal cancer, Gastroenterology, Government, Patient, Physician, Capitol Hill, Mall, Disease, Survivor, Friends, White House, Envision Healthcare, Congress, Endoscopy, MD, National Mall, White, Cancer survivor, Ageing, Large intestine, Mobile phone, Nursing

John Popp, MD, AMSURG Medical Director, has been invited to attend the Cancer Moonshot Colorectal Cancer Forum hosted by the White House on March 10.

Key Points: 
  • John Popp, MD, AMSURG Medical Director, has been invited to attend the Cancer Moonshot Colorectal Cancer Forum hosted by the White House on March 10.
  • He will join industry leaders in addressing ways to improve colorectal cancer screening.
  • The event follows the Biden-⁠Harris Administration’s recent announcement that it is reigniting the Cancer Moonshot , which in part aims to increase colorectal cancer screening for people aged 45 to 75.
  • Colorectal cancer is the second leading cause of cancer death in the U.S., and it’s on its way to becoming the leading cause.

AMSURG Performs More Than 1 Million Colonoscopies in 2022, Helping Prevent Colorectal Cancer and Save Lives

Retrieved on: 
Monday, March 6, 2023
Managed Care, Men, Radiology, Family, Pharmaceutical, Oncology, Consumer, Hospitals, Surgery, Other Consumer, Women, Seniors, Health, MD, Mount Sinai, Colorectal cancer, Abdominal pain, Colonoscopy, Gastroenterology, Red Bank, Icahn School of Medicine at Mount Sinai, American Cancer Society, Colon, Endoscopy, Risk, Inflammatory bowel disease, Large intestine, Patient, COVID-19, Polyp, Cancer, Research, Envision Healthcare, Dairy

AMSURG and its national network of gastroenterologists and colorectal surgeons performed more than 1 million colonoscopies in 2022, helping people prevent, detect and overcome colorectal cancer.

Key Points: 
  • AMSURG and its national network of gastroenterologists and colorectal surgeons performed more than 1 million colonoscopies in 2022, helping people prevent, detect and overcome colorectal cancer.
  • Colorectal cancer is the second leading cause of cancer death in the U.S., and the American Cancer Society predicts that 52,550 people will die from it in 2023.
  • Timely screenings – especially colonoscopies – play a significant role in an individual’s chance of beating colorectal cancer.
  • “Our care teams have made a meaningful impact in countless patients’ lives, helping them prevent colorectal cancer, detect it and continue ongoing surveillance,” said John Popp, MD, Medical Director for AMSURG.